Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $716962.0.

  • InMed Pharmaceuticals' Cost of Revenue fell 703.59% to $716962.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 607.06%. This contributed to the annual value of $3.2 million for FY2025, which is 745.74% down from last year.
  • InMed Pharmaceuticals' Cost of Revenue amounted to $716962.0 in Q3 2025, which was down 703.59% from $728056.0 recorded in Q2 2025.
  • InMed Pharmaceuticals' Cost of Revenue's 5-year high stood at $1.3 million during Q2 2023, with a 5-year trough of $127308.0 in Q1 2022.
  • In the last 5 years, InMed Pharmaceuticals' Cost of Revenue had a median value of $749640.5 in 2024 and averaged $670515.0.
  • Per our database at Business Quant, InMed Pharmaceuticals' Cost of Revenue skyrocketed by 56092.78% in 2023 and then plummeted by 3798.69% in 2024.
  • InMed Pharmaceuticals' Cost of Revenue (Quarter) stood at $153537.0 in 2021, then soared by 120.55% to $338620.0 in 2022, then skyrocketed by 170.53% to $916058.0 in 2023, then dropped by 28.96% to $650813.0 in 2024, then increased by 10.16% to $716962.0 in 2025.
  • Its Cost of Revenue stands at $716962.0 for Q3 2025, versus $728056.0 for Q2 2025 and $1.1 million for Q1 2025.